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Introduction
Sepsis is the systemic inﬂ  ammatory response to infection. 
Th   e clinical syndrome can range from mild constitutional 
upset to overt septic shock with the failure of multiple 
organ systems, reﬂ   ecting the complex pathogenesis of 
sepsis involving immunological and coagulation 
pathways [1,2]. Th  e burden from sepsis remains high 
with worldwide incidence ranging from 0.5 to 1.5 per 
1,000 population, a mortality rate at 1 month of 30% from 
recent randomised trials, and costs of between $11,500 
and $22,000 per hospital episode [3,4]. Th   e modulation of 
single inﬂ  ammatory pathways (for example, TNFα [5]) 
and generalised immune suppression with steroids [6,7] 
has proved unsuccessful in the past, reﬂ  ecting  the 
complex pathogenesis of sepsis and leading to a re-
evalua  tion of the mechanisms that may underlie it. 
Several laboratory and observational studies have shown 
that accelerated apoptosis occurs in sepsis and may 
explain both the organ failure that is a feature of it and 
secondary infections that can intervene [8-10].
Th   e haematopoietic growth factor erythropoietin 
(EPO) reduces apoptotic cell death and attenuates 
inﬂ  am  mation, with cytoprotective eﬀ  ects in both animal 
and human models of ischaemic injury. EPO also has 
putative vasopressor actions. A complete summary of the 
extra-haemopoietic eﬀ  ects of EPO in speciﬁ  c organs is 
beyond the scope of the present discussion so readers are 
referred to reviews [11-13]. Th   e present commu  nication 
seeks to explain the role of apoptosis in sepsis and to 
summarise the available data on EPO and its extra-
haemopoietic eﬀ  ects in sepsis and critical illness.
Cell death in sepsis
Apoptosis is programmed cell death, distinct from 
necrosis, limiting damage around the penumbra of an 
injury. Th  is process is important in the homeostasis of 
the inﬂ   ammatory response, and delayed neutrophil 
apoptosis has been implicated in mediating tissue 
damage in acute respiratory distress syndrome and sys-
temic inﬂ   ammatory response syndrome [14-16]. Th  at 
said, accelerated apoptosis has been clearly identiﬁ  ed in 
postmortem studies of septic patients in lymphoreticular 
tissues and in gut columnar epithelium, conspicuously 
absent in nonseptic controls [17].
A postulate is that death from sepsis occurs due to 
over  whelming infection in the face of immuno-
suppression due to lymphocyte apoptosis [18]. Indeed, 
outcome is worse in septic patients with lymphopaenia 
[19] and in those with evidence of lymphocyte apoptosis 
[20]. Apotosis of gut epithelium may also lead to bacterial 
and endotoxin translocation due to a breach in the 
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© 2010 BioMed Central Ltdintegrity of the bowel wall. Apoptotic cells per se may 
have detrimental eﬀ   ects as transfusion of apoptotic 
splenocytes into septic mice worsens outcome compared 
with both controls and transfusion of necrotic spleno-
cytes [21].
Modulation of diﬀ  erent parts of the apoptosis pathway 
has been shown to alter outcome in animal models of 
sepsis: inhibition of Fas/Fas ligand binding, a known 
promoter of apoptosis, leads to attenuation of liver 
damage in septic mice [22,23], and overexpression of the 
anti-apototic B-cell lymphoma protein 2 (Bcl-2) in trans-
genic mice reduces lymphocyte apoptosis and im  proves 
survival in response to sepsis [24]. Caspases are integral 
in the downstream promotion of cellular apoptosis. Th  e 
use of caspase inhibitors has been shown to improve 
survival and reduce lymphocyte apoptosis in one model 
of sepsis [25] and to reduce apoptosis in acute lung and 
kidney injury [26].
Both immune-mediated and coagulation pathways are 
deranged in sepsis, the endothelium being pivotal to 
these processes [1]. Studies in which endothelial cell lines 
were infected with bacteria such as Escherichia coli and 
Staphylococcus aureus have shown consistent evidence of 
endothelial cell apoptosis [27-31], but in vivo work has 
failed to show consistent results [32,33] with the easy 
detachment of cells into the media, making detection 
diﬃ   cult.
Although recent data have questioned the balance 
between apoptosis and necrosis in the outcome from 
sepsis [34], on balance the data would suggest that 
attenuation of apoptosis is a fruitful line of investigation 
to pursue.
Erythropoietin
EPO is a 30.4 kDa glycoprotein hormone and member of 
the type I cytokine family. Its main function is the 
regulation of red blood cells through a speciﬁ  c  cell 
surface receptor (EpoR). Stimulation of EpoR reduces 
apoptosis of red cells via the Janus tyrosine kinase 2 
(Jak-2) pathway, increasing their lifespan [35]. After 
successful clinical trials of EPO in the treatment of 
anaemia of end-stage renal failure [36,37], its use has 
been extended to the treatment of anaemia in malig-
nancy, human immunodeﬁ   ciency virus infection, 
prematurity and myelodysplasia [13].
Th   e principle site of secretion is the peritubular inter-
stitial ﬁ   broblasts of the renal cortex in response to 
stabilisation and DNA binding of hypoxia-inducible 
factors [38]. Several inﬂ   ammatory cytokines increase 
expression of EpoR and EPO, including insulin-like 
growth factor, IL-1β, IL-6 and TNFα, suggesting a role in 
inﬂ  ammation [39-41]. Embryologically, EPO-EpoR has a 
signalling role in angiogenesis and brain development, 
and EpoR is widely expressed in the brain, retina, heart, 
kidney, smooth muscle cells, myoblasts and vascular 
endothelium, suggesting pluripotent eﬀ   ects in normal 
health and development [13].
Anti-apoptotic eff  ects of erythropoietin
After evidence of a beneﬁ  cial  eﬀ   ect of systemic EPO 
administration on the course of ischaemic brain injury in 
mice [42], several animal models of ischaemia/reper-
fusion have conﬁ  rmed the cellular, anti-apoptotic eﬀ  ects 
of EPO in neuronal, renal, endothelial and cardiovascular 
damage [43,44]. In these models, EPO prevents apoptosis 
via a number of pathways, dependent on receptor 
activation by the Jak-2 pathway (see Figure 1). Protein 
kinase B, an important downstream substance in the 
Jak-2 pathway, regulates multiple pro-apoptotic and anti-
apoptotic intermediates, including glycogen synthase 
kinase-3β (GSK-3β), Bcl-2-related death promoter, and 
the pro-apoptotic forkhead box transcription factor O3a, 
rendering it unable to activate transcription and nuclear 
genes involved in apoptosis. EPO increases the expres-
sion of several intrinsic inhibitors of apoptosis, including 
Bcl-2, X-linked inhibitor of apoptosis protein and proto-
oncogene serine/threonine-protein kinase 3. In neuronal 
cells, stabilisation of the transcription factor NF-κB is 
essential for the anti-apoptotic eﬀ  ects of EPO, although 
this not been seen in other cell types.
A carbamylated form of EPO (CEPO), which has low 
aﬃ     nity for the classical EpoR and does not cause 
erythropoiesis, has shown signiﬁ  cant  anti-apoptotic 
eﬀ  ects in culture and organ protection in a variety of 
animal models [45,46]. It is postulated that CEPO signals 
through a heteroreceptor involving the EpoR and two 
common β chains of the IL-3 receptor (CD133) [11]. 
Th   ere are clear advantages to an agent that harnesses the 
beneﬁ  cial properties of EPO without signiﬁ  cant erythro-
poiesis, and also does not cause platelet and endothelial 
activation and hence is associated with a less thrombo-
genic proﬁ  le [47]. Pyroglutamate-helix B surface peptide 
(ARA 290, Araim Pharmaceuticals, Ossining, NY, USA) 
is an erythropoietin analogue modelled on a portion of   
its 3D structure and although only 11 amino acids long 
seems to show good neuroprotective and tissue protec-
tive eﬀ  ects without eliciting signiﬁ  cant haemo  poietic or 
endothelial eﬀ  ects thought to underlie the prothrombotic 
tendency of EPO [48]. While these molecules are attrac-
tive alternatives to EPO with the potential for less side 
eﬀ  ects these endothelial and pressor eﬀ  ects may actually 
be beneﬁ  cial in sepsis syndromes.
Vascular eff  ect of erythropoietin
Septic shock is associated with peripheral vasoplegia 
[49], requiring catecholamines such as norepinephrine to 
maintain blood pressure and organ perfusion [50]. Th  e 
large doses required may cause unwanted side eﬀ  ects, 
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and digital gangrene [51]. Vasopressin oﬀ  set the dose of 
norepinephrine required to maintain adequate mean 
arterial pressure (MAP) in a large randomised study [52]; 
however the side eﬀ  ect  proﬁ   le was similar to norepi-
nephrine suggesting a role for other pressor agents.
Twenty-ﬁ  ve to 30% of patients with renal failure treated 
with EPO develop worsening hypertension [53]. Postu-
lated mechanisms include alteration in blood viscosity, 
enhanced vascular reactivity and improved vasocon-
striction following correction of anaemia [54]. Th  ere is 
accumulating evidence, however, of direct vaso  pressor 
eﬀ  ects of EPO, through interaction with EpoR expressed 
on vascular smooth muscle cells [13]. EPO causes an 
increase in the cytosolic-free calcium in vascular smooth 
muscle cells, and augments the eﬀ  ects of angiotensin II 
[55,56] in addition to upregulating angio  tensin II 
receptor expression [57]. Synergistic eﬀ  ects on cellular 
calcium levels are seen with endothelin-1 and nor-
adrenaline [56,58].
Activation of inducible nitric oxide synthase leading to 
increased nitric oxide plays an important role in the 
pathogenesis of vasodilatory shock [49]. EPO attenuates 
the eﬀ  ects of interleukin-1β on nitric oxide synthase via 
direct stimulation of EpoR, providing an alternative 
pressor eﬀ  ect [59,60]. In addition, EPO increases stability 
of endogenous nitric oxide synthase via protein kinase B-
dependent phosphorylation, and induces increased 
Figure 1. Anti-apoptotic pathways regulated by erythropoietin. The binding of erythropoietin (EPO) to its dimerised cell surface receptor 
causes conformational change, leading to activation and autophosphorylation of Janus-tyrosine kinase-2 (Jak2). Jak2 phosphorylates nine tyrosine 
residues in the intracellular portion of the receptor, which allows interaction with signal transducers and activators of transcription protein (STATs) 
signalling molecules, and activates phosphoinostitol-3 kinase (PI3K) and hence protein kinase B (AKT). AKT regulates multiple pro-apoptotic and 
anti-apoptotic intermediates, including glycogen storage kinase-3β (GSK-3B), B-cell lymphoma protein 2 (Bcl-2)-related death promoter (Bad) and 
the pro-apoptotic forkhead box transcription factor O3a (FOXO3a), rendering it unable to activate transcription of apoptotic signalling genes. STATs 
cause transcription of the anti-apoptotic molecules Bcl-2 and proto-oncogene serine/threonine-protein kinase 3 (PIM-3). EPO also activates NF-κB, 
possibly in a cell-type-specifi  c manner, which alters transcription of pro-apoptotic and anti-apoptotic proteins including inhibitor of apoptosis 
proteins. ASK-1, apoptosis signal-regulating kinase 1; Bcl-xL, B-cell lymphoma extra large; cIAP, baculoviral inhibitor of apoptosis protein repeat-
containing protein; eNOS, endogenous nitric oxide synthase; EpoR, erythropoietin receptor; HSP70, heat shock protein 70; XIAP, X-linked inhibitor of 
apoptosis protein.
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wall tension as shown in isolated rat mesenteric and renal 
resistance arteries [61]. Th  is appears independent of α-
adrenergic stimulation, oﬀ  ering a diﬀ  erent pathway for 
vasoplegia correction. In haemorrhagic shock, the 
selective α-adrenergic agonist phenylephrine has attenu-
ated eﬀ  ects in intact aortic rings. Pretreatment with EPO 
reverses this eﬀ  ect with signiﬁ  cant increases in the MAP 
and length of survival of rats [62].
No randomised study has examined the vasopressor 
eﬀ  ects of EPO in humans; however, in patients with renal 
failure and on haemodialysis there is a consistent increase 
in the MAP in response to a single dose of EPO, mediated 
in part by an increase in the serum endothelin-1 level 
[63]. In addition, EPO led to a marked increase in the 
vasoconstricting eﬀ  ects of noradrenaline determined by 
forearm blood ﬂ  ow in chronic renal-failure patients [64]. 
In a case series of two patients with vasodilatory shock, 
administration of 10,000 IU EPO every 4 hours for 24 
hours resulted in a brisk and sustained increase in MAP 
and a rise in the peripheral vascular resistance [65]. EPO 
has vaso  constrictor eﬀ   ects that could be useful in 
improving MAP and blood ﬂ  ow to the tissues in severe 
sepsis and septic shock where vasopressors are required.
Anti-infl  ammatory and cytoprotective eff  ects of 
erythropoietin
Th   ere are consistent data from the literature conﬁ  rming 
anti-inﬂ  ammatory and cytoprotective eﬀ  ects of EPO in 
many diﬀ  erent animal models of sepsis and inﬂ  ammation. 
Both pre and post insult, the administration of EPO 
attenuates tissue injury. In a rat model of necrotising 
pancreatitis, EPO led to a reduction in all features of 
sepsis-induced acute lung injury, including circulating 
proinﬂ   ammatory cytokines, polymorphonuclear cell 
accu  mulation and lipid peroxidation, with better mainte-
nance of microvascular cellular integrity [66]. Similar 
attenuation of inﬂ  ammation has been shown in response 
to zymosan (a Toll-like receptor-2 agonist) in mice with 
reduced local and systemic signs of inﬂ  ammation and 
organ dysfunction and lowered levels of TNF and IL-1β 
compared with control animals [67]. In a rat model of 
sepsis induced by intraperitoneal lipopolysaccharide, the 
Toll-like receptor-4 ligand, the eﬀ  ects on lymphocyte and 
thymic apoptosis as well as serum nitric oxide production 
were reduced in the group of animals pretreated with 
EPO [68].
In murine models of sepsis due to caecal ligation and 
puncture, administration of EPO post insult is associated 
with a fourfold improvement in the glomerular ﬁ  ltration 
rate mediated by protective eﬀ   ects on superoxide 
dismutase [69]. In addition, improvements in perfused 
capillary density and tissue hypoxia measured by intra-
vital micros  copy and changes in nicotinamide adenine 
dinucleotide phosphate ﬂ  uorescence have been demon-
strated, suggest  ing improved microvascular integrity [70]. 
Aoshiba and colleagues examined the eﬀ   ects of large 
doses of EPO in attenuating both increasing lethal doses 
of lipopoly  saccharide and caecal ligation and puncture. 
Th   ere was improved survival in EPO-treated mice, with 
less apop  tosis in the lungs, liver, small intestine, thymus 
and spleen along with reduced inducible nitric oxide 
synthase expres  sion [71].
Data from clinical studies on patients with myeloma 
[72] and patients on haemodialysis [73] have shown that 
EPO has direct eﬀ  ects on immunity. In a murine model 
of myeloma, EPO promotes the development of an anti-
tumour speciﬁ   c immune response via activated CD8+ 
T  cells [74]. Little is known on the expression and 
signalling of the EpoR in immune cells, however, as the 
classical EpoR was not detected on human lymphocytes 
by proofreading PCR [75] and these observed eﬀ  ects may 
be mediated by other cells. Th  is is supported by the 
expression and role of the EpoR on macrophages during 
wound repair [76].
While positive results in animal models do not always 
correlate with clinical outcomes, it appears that EPO has 
signiﬁ  cant cytoprotective eﬀ  ects mediated by anti-apop-
totic and immune mechanisms that could be bene  ﬁ  cial in 
sepsis syndromes. Th  ese  eﬀ  ects remain to be conﬁ  rmed 
in clinical practice.
Clinical studies of erythropoietin
In septic patients, EPO concentrations are elevated above 
control levels [77-79] but response to anaemia is blunted 
[80,81], with lower levels than in otherwise well, anaemic 
patients. In clinical studies, concentrations of 300 to 
500  IU/kg have been used, with peak serum levels 
reaching over 5,500 U/l in one trial and 200 times greater 
than control in another [82,83]. Once-weekly dosing with 
40,000 IU EPO in intensive care patients gave mean 
serum levels upward of 800 IU/l in the blood, similar to 
levels found in healthy controls [84,85]. Th  is compares 
with peak levels of 150 IU/l in septic shock patients [79].
Many patients with severe sepsis require treatment in 
critical care units. Th  ere are high-quality data on the 
eﬀ  ects of EPO on transfusion requirements in critical 
illness. Anaemia in critically ill patients evolves over time 
such that transfusion is required in 35% of patients 
requiring intensive care for >5 days [86].
Th  e largest randomised study of EPO in critically ill 
patients had signiﬁ   cant numbers of septic patients 
(188/1,460 patients) [87,88]. Recruitment was 48 hours 
after intensive care unit admission with EPO being 
commenced between days 3 and 5. Th   ere was no a priori 
analysis of mortality in septic patients or on total pressor 
requirements. EPO was associated with a lower mortality 
at day 29 (8.5% vs. 11.4%), and an analysis of the 793 
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tion in mortality (relative risk, 0.4; 95% conﬁ  dence 
interval, 0.23 to 0.69). It is interesting to speculate why 
this might be. Animal models of traumatic and compres-
sive peripheral and central nerve injury and models of 
wound healing show consistent cytoprotective eﬀ  ects, 
with EPO correlating with reduced apoptosis, improved 
wound healing and reduced inﬂ   ammation [11,89]. In 
addition, rat models of haemorrhagic shock show 
improve  ments in haemodynamic stability and markers of 
organ dysfunction [62,90]. Th  ese  eﬀ  ects may underlie the 
improved outcome; however, clinically relevant throm-
botic events were commoner in EPO-treated patients, 
with a hazard ratio of 1.41 (95% conﬁ  dence interval, 1.06 
to 1.86) occurring in 120/728 patients in the EPO-treated 
group versus 83/720 in the control group. Th  is  prothrom-
botic tendency has been recognised in other conditions 
(see below) and raises concerns about target haemoglobin 
concentrations and dosing.
A meta-analysis identiﬁ  ed nine trials of EPO in acutely 
unwell patients [91], a signiﬁ  cant minority of whom had 
sepsis [84,87,88,92-97]. Recruitment into these studies 
occurred when either a transfusion trigger was met or 
after a given time in intensive care (see Table 1). No 
mortality beneﬁ  t (odds ratio, 0.81; 95% conﬁ  dence interval, 
0.65 to 1.01) was observed among the studies of high 
methodological quality. Importantly, EPO doses >40,000 
units weekly were associated with a trend towards more 
harm. Transfusion independence showed an odds ratio of 
0.73 (95% conﬁ  dence interval, 0.64 to 0.84) in favour of 
EPO, with a reduction of 0.41 units of blood transfused. 
Inter  pretation of these data in light of this discussion is 
problematic as anticipated non  haemo  poeitic beneﬁ  ts  of 
EPO are likely to accrue from adminis  tration in the early 
stages of sepsis. Nonetheless, data from these studies 
inform on potential harm, dosing and pharmacokinetics. 
In addition, changes in transfusion prac  tice in 1999 
accepting a lower threshold for transfusion make studies 
before and after this date diﬃ   cult to reconcile [98].
Clinical data supporting a cytoprotective eﬀ  ect have 
been shown in cerebrovascular accidents, with those 
patients administered EPO 8 hours after the onset of 
their stroke having better clinical and radiological out-
comes [82]. Following animal evidence of anti  apoptotic 
eﬀ   ects in cerebral malaria [99,100], EPO is currently 
being investigated as an adjunctive treatment in a phase 
III trial of cerebral malaria in children in Mali 
[ClinicalTrials.gov identiﬁ  er NCT00697164].
Potential side eff  ects of erythropoietin
Speculation on the beneﬁ  t of a novel treatment has to be 
weighed against potential harm. Data from renal patients 
suggest that aiming for haemoglobin concentrations 
>12 g/dl worsens the risk of thrombotic events [101,102]. 
An increase in clinically relevant thrombotic events has 
been shown in critically ill patients, with a 1.5 times 
increase (7.8% vs. 5.3%) in deep vein thrombosis and a 2.5 
times increase in myocardial infarction (2.1% vs. 0.8%) 
[91]. Th   is occurred in the presence of haemoglobin con-
cen  trations <10 g/dl, suggesting that the prothrom  botic 
eﬀ  ects are not wholly dependent on blood viscosity but 
reﬂ   ect platelet and endothelial cell changes [13]. As 
microvascular thrombosis is felt to contribute to organ 
failure and coagulopathy in sepsis [1,2], EPO could 
exacerbate this problem. Th  e use of non-erythropoietic 
derivatives such as CEPO may avoid many of the adverse 
eﬀ  ects observed with EPO.
EPO has been associated with worsening of hyper-
tension and hypertensive encephalopathy [13] but these 
are less common with treatment nowadays. As sepsis is 
associated with vasodilatory shock, vasopressor eﬀ  ects 
could be seen as a positive side eﬀ  ect (see above).
Th   e use of EPO has been shown to worsen outcome in 
certain cancers due to increased thromboembolic risk 
and possibly EPO-induced tumour progression [103]. 
Th   is observation raises concerns over EPO use in patients 
with malignancies who develop sepsis. If used earlier in 
the course of sepsis, EPO may uncover other unwanted 
Table 1. Summary of trials of erythropoietin in acutely critically ill patients
Year Reference  ntotal  nsepsis Enrolment  Dose  Duration
1995  Still and colleagues [96]  40  0  >3 days  150 IU/kg three times/week  30 days
1998  Gabriel and colleagues [93]  21  ns  ICU admission  600 IU/kg three times/week  Maximum 3 weeks
1999  Corwin and colleagues [92]  80  6  Day 3  300 IU/kg daily for 5 days  Maximum 6 weeks
2000  van Iperen and colleagues [97]  36  23  Hb <11.2 g/dl  300 IU/kg alternate days for 5 days  5 doses
2002  Corwin and colleagues [87]  1,352  105  Day 3  40,000 IU/week  Maximum 3 weeks
2005  Georgopoulos and colleagues [94]  148  ns  Hb <12.0 g/dl  40,000 IU/week  Maximum 3 weeks
2006  Vincent and colleagues [84]  68  14  HCT <0.38  40,000 IU/week  Maximum 4 weeks
2006  Silver and colleagues [95]  86  25  <7 days  40,000 IU/week  Maximum 12 weeks
2007  Corwin and colleagues [88]  1,460  188  Day 3/4  40,000 U/week  Maximum 3 weeks
Number of patients with sepsis is shown and the timing of erythropoietin use. Hb, haemoglobin; HCT, haematocrit; ICU, intensive care unit; ns, not specifi  ed.
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aplasia due to EPO antibodies are fortunately rare [13] 
but clinicians using this drug in a new way should 
monitor closely for adverse side eﬀ  ects.
Conclusion
Attempts at immune modulation in sepsis have proved 
disappointing for many years, leading to a reappraisal of 
the mechanisms underlying sepsis in the search for novel 
therapies. Apoptosis is pivotal in the relative immuno-
suppression that can lead to secondary infection and 
superinfection in sepsis. EPO has known anti-apoptotic 
eﬀ   ects that have shown, in both animal and clinical 
models of disease, to translate into clear cytoprotective 
eﬀ  ects. Coupled with this observation, EPO appears to 
have in vitro and in vivo eﬀ  ects on vasomotor function, 
augmenting the eﬀ   ects of other mediators such as 
catecholamines and endothelins. Reliable clinical data in 
critically ill patients have led to useful information on the 
pharmacokinetics [84,85] and the potential for harm 
[87,88,91].
An observational, prospective cohort study is currently 
underway to examine the eﬀ  ects of EPO on microvascular 
inﬂ  ammatory response in severe sepsis [Clinical trials.
gov identiﬁ  er NCT01087450]. We argue that the weight 
of evidence has reached a point where further phase II 
and III clinical trials on EPO would seem the obvious 
next step. We believe most beneﬁ  t would accrue from the 
administration of EPO within 24 hours of the onset of 
sepsis and organ dysfunction. Optimal absorption would 
be via the intravenous route and dosing could be guided 
from clinical studies where ranges between 150 and 
600 IU/kg have been used previously. We would suggest 
doses of 400 IU/kg given on consecutive days for 3 days 
with close monitoring for thromboembolic side eﬀ  ects 
[82,92,93,97].
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